NIPAPORN BUADAENG: Open Payments
NPI 1366939019 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,413 in 60 payments from 25 companies in 2025. Trend: 2023 $558 · 2024 $951 · 2025 $1,413
Food & beverage: $1,413
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 4 | $180 |
| Amgen Inc. | 5 | $126 |
| PFIZER INC. | 6 | $123 |
| Axsome Therapeutics, Inc. | 4 | $107 |
| Otsuka America Pharmaceutical, Inc. | 4 | $107 |
| ABBVIE INC. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Almatica Pharma LLC | 3 | $70 |
| Alkermes, Inc. | 2 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $52 |
Products named: FREESTYLE LIBRE 3, REXULTI, TRINTELLIX, OTEZLA, LOREEV XR, ELIQUIS, Auvelity, ARISTADA.
Industry payments across NV — which companies pay providers there.
